Clinical Trial Detail

NCT ID NCT02756897
Title Venetoclax and Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLL)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

CLL/SLL

Therapies

Ibrutinib + Venetoclax

Age Groups: adult

No variant requirements are available.